Lewoyte depleto

UNIVERSAL LEUCOCYTE DEPLETION - ISSUES TO CONSIDER (and by whom)

1. Availability of filters, how to evaluate, tendering process. Role of COBE LRS. -(NBS/SACBC)

2. What will be the specification - absolute numbers, subsets (later), minimum and maximum interval between collection and leucocyte depletion. (SACBC/SACTTI) - must be done prefuely us

3. Methodologies for plasma - for fractionation

- for FFP (whole blood filtration/methylene blue etc) NBS/SACBC

4. How to QC on a large scale, even with 1% QM? Nageotte/flow cytometry. Validation of methods Development of 'go/no-go' level for simplicity. Development of 'LEUQAS' exercises to monitor cell counting performance. SACBC/NBS

5. Development of research methods for absolute counting to low levels; subset analysis etc. NBS/SACBC

6. How best to monitor risk of bacterial contamination? SACBC/SACTTI

7. What to do re BCSH Guidelines on Leucocyte Depletion (in press!). (have spoken to Paul Kelsey - they will go ahead meantime, but we can update him at Task Force meeting next week).

8. Complete rewrite of all Red Book Component Specs! SACBC

9 Will we need to continue CMV testing? SACBC/SACTTI

FOA don't accept this as equality.

10. What can we say about the risk of HTLV? SACBC/SACTTI (Further studies planned at Cambridge)

11. Can we organise a prospective study to compare rates of post-op infection over the next 6-12 months with those seen after leucocyte depletion? NBS/Clinical Directors (joint consultant task?)

Lorna Williamson

10/11/97

? Development of Zurich Reignostic Test. in

NHBT0009286 002 0001